07:35 AM EDT, 03/17/2025 (MT Newswires) -- Avidity Biosciences ( RNA ) said Monday that topline data from the phase 1/2 EXPLORE44 trial of del-zota to treat Duchenne muscular dystrophy showed "consistent, statistically significant improvements in dystrophin, exon skipping and creatine kinase."

The biopharmaceutical company said del-zota also demonstrated favorable safety and tolerability in the dose cohorts. It also said it will present the data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference this week.

Shares of Avidity Biosciences ( RNA ) were up 2.9% in recent premarket activity.

Price: 32.00, Change: +0.89, Percent Change: +2.86